01 jun: UPDATE: FTC Says Graco Must Sell Illinois Tool's Finishi..
01 jun: Canada's Senate Passes Back-To-Work Bill To End CP Rail ..
01-06-2012 00:14:00

UK Regulator Draft Guidance Recommends Bayer's Xarelto For Blood Clots

Relateret indhold
Relateret debat
24 feb - 
We arrange Following Bank Instruments Letter of Credit ..
24 feb - 
We arrange Following Bank Instruments Letter of Credit ..
24 feb - 
We arrange Following Bank Instruments Letter of Credit ..

FRANKFURT -(Dow Jones)- The U.K. drug regulator has recommended the use of Xarelto, a drug produced by a unit of Bayer AG (BAYN.XE), to treat blood clots, according to draft final guidance published Friday.

The guidance is likely to result in a recommendation from the National Institute for Health and Clinical Excellence, known as NICE, meaning the U.K. public health-care system will offer the drug and pay for it. The draft guidance is now with consultees, who have the opportunity to appeal against it.

"Bayer Healthcare welcomes this draft final appraisal determination recommendation from NICE because it simplifies the treatment of venous blood clot treatment for physicians and their patients," Bayer spokeswoman Astrid Kranz said.

Earlier, NICE had asked Bayer to provide more information on the drug. The move follows a May 22 approval for Xarelto for stroke prevention and systemic embolism in people with atrial fibrillation.

If the final approval is given, Xarelto, also known as Rivaroxaban, may then be offered as an alternative to injectable anticoagulants such as low-molecular-weight heparin or fondaparinux sodium, overlapped with a vitamin-K antagonist, such as warfarin.

It is estimated that there will be over 46,000 cases of acute deep vein thrombosis, or DVT, in England and Wales during 2012, rising to nearly 50,000 by 2016 due in large part to the aging population, NICE said.

"Xarelto is the first only novel oral anticoagulant offering a unique single drug solution for the treatment of DVT in adults," Kranz said.

On May 24, Bayer confirmed it expects peak sales of Xarelto of above EUR2 billion annually. The drug, which is being co-developed by Bayer and U.S. drug maker Johnson & Johnson (JNJ), is a rival of Boehringer Ingelheim GmbH's Pradaxa.

-By Monica Houston-Waesch, Dow Jones Newswires; +49 69 29 725 504; nikki.houston@dowjones.com

(END) Dow Jones Newswires

May 31, 2012 18:14 ET (22:14 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/middag: Største skvulp er dønninger efter WDH-regnskab

02-03-2015 11:40:55
Efterdønningerne efter et godt regnskab fra William Demant Holding torsdag i sidste uge sørger mandag formiddag for, at der er lidt skvulp i et ellers meget sti..

Novo: Hæver udbudsinterval for NNIT-aktier - NY

02-03-2015 08:44:36
Novo Nordisk har som sælgende aktionær besluttet at forhøje det indikative udbudskursinterval for aktierne i NNIT til 120-130 kr. fra tidligere 100-120 kr. per ..

FLSmidth: Kobberprisen gjorde comeback i februar

27-02-2015 15:57:04
Kobberprisen har gjort et lille comeback i februar, hvor det for FLSmidth så vigtige metal har klaret sig bedst blandt industrimetallerne noteret på London Meta..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo: Hæver udbudsinterval for NNIT-aktier - NY
2
Vestas: Analytikere trimmer 2015-estimater
3
Vestas' bestyrelse vil have 10 pct. mere i løn
4
Aktier/tendens: Handlerne går rolig åbning i møde
5
Maersk Drilling indgår hensigtserklæring om ledigt boreskib

Relaterede aktiekurser

Johnson & Johnson 102,51 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
2. marts 2015 12:12:11
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150225.2 - EUROWEB4 - 2015-03-02 12:12:11 - 2015-03-02 12:12:11 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x